Despite flat earnings and challenging market conditions,Cresco Labs Inc.(OTC:CRLBF) remains an "Overweight" stock, according to analysis firmZuanic & Associates. In his latest report, Zuanic underscores Cresco's strong positioning in emerging adult-use markets such as Pennsylvania and Ohio while identifying valuation advantages that set the company apart.

Cresco trades at 5.5x forward EBITDA, belowGreen Thumb Industries Inc.(OTC:GTBIF) at 7x andCuraleaf Holdings Inc.(OTC:CURLF) at 10x.

"This discount presents an appealing entry point for investors looking beyond short-term volatility," Zuanic writes.

• Get Benzinga's exclusive analysis and the top news about the cannabis industry...